PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients
AbstractBackground: Bevacizumab-based regimens are used as standard treatments for colorectal cancer. Unfortunately, there are no established predictive markers for bevacizumab response. Methods: Tumor samples from 36 metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy were analyzed by next-generation sequencing of all coding exons of more than 400 genes. Single gene and signaling pathway analyses were performed to correlate genomic data with response. Results: Among the genes most frequently mutated in our cohort, only mutations in PTPRT, a phosphatase involved in JAK/STAT signaling, were associated with response status, with deleterious mutations being enriched in non-responders. Pathway analysis revealed that deleterious mutations in genes of the JAK/STAT pathway, namely in PTPRT and the related gene PTPRD, correlated with resistance. Mutations in RTK/PI3K/RAS, Wnt and TGFβ pathways did not associate with response. Lack of response was observed in all patients with deleterious mutations or copy number loss of PTPRT/PTPRD (n = 10), compared to only 30.8% (n = 8) of patients without such alterations (relative risk, 3.25; 95% CI, 1.83–5.79, p = 0.0003). Similarly, PTPRT/PTPRD deleterious alterations were associated with shorter progression-free survival, an association that was retained in multivariate analysis (HR, 3.33; 95% CI, 1.47–7.54; p = 0.0038). Conclusion: Deleterious alterations in PTPRT/PTPRD are potential biomarkers for bevacizumab resistance. View Full-Text
- Supplementary File 1:
ZIP-Document (ZIP, 78 KB)
Share & Cite This Article
Hsu, H.-C.; Lapke, N.; Chen, S.-J.; Lu, Y.-J.; Jhou, R.-S.; Yeh, C.-Y.; Tsai, W.-S.; Hung, H.-Y.; Hsieh, J. .-H.; Yang, T.-S.; Thiam, T.K.; You, J.-F. PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients. Cancers 2018, 10, 314.
Hsu H-C, Lapke N, Chen S-J, Lu Y-J, Jhou R-S, Yeh C-Y, Tsai W-S, Hung H-Y, Hsieh J -H, Yang T-S, Thiam TK, You J-F. PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients. Cancers. 2018; 10(9):314.Chicago/Turabian Style
Hsu, Hung-Chih; Lapke, Nina; Chen, Shu-Jen; Lu, Yen-Jung; Jhou, Ren-Shiang; Yeh, Chien-Yuh; Tsai, Wen-Sy; Hung, Hsin-Yuan; Hsieh, Jason .-H.; Yang, Tsai-Sheng; Thiam, Tan K.; You, Jeng-Fu. 2018. "PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients." Cancers 10, no. 9: 314.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.